



November 09, 2023

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

**Sub: Press Release on Financial Results for Quarter and Half Year ended September 30, 2023.**

Dear Sir/Madam,

This is in continuation of our letter dated November 08, 2023 regarding Outcome of Board Meeting held on November 08, 2023 wherein the Company had approved the Un-Audited Financial Results for the Quarter and Half Year ended September 30, 2023.

In this regard, please find enclosed the Press Release made by the Company on the Highlights of Financial Results for the Quarter and Half Year ended September 30, 2023.

Kindly take the above on records.

Thanking you.

Yours faithfully,  
**For Vaishali Pharma Limited**

**Atul Vasani**  
**Managing Director**  
**DIN: 02107085**



## Vaishali Pharma's H1 FY24 Revenue Up By 9%

**Mumbai, November 8, 2023:** Vaishali Pharma Limited (NSE – VAISHALI), engaged in production and marketing of a diverse range of pharmaceutical products, announced its unaudited Financial Results for H1 & Q2 FY24.

### Key Financials at a Glance:

#### H1 FY24

- Total Income at ₹ 26.65 Cr
- EBITDA at ₹ 5.62 Cr
- EBITDA Margin is 21.11 %
- Net Profit at ₹ 3.29 Cr
- Net Profit Margin is 12.34%
- EPS at ₹ 3.10

#### Q2 FY24

- Total Income at ₹ 12.86 Cr
- EBITDA at ₹ 2.95 Cr
- EBITDA Margin is 22.97 %
- Net Profit at ₹ 1.70 Cr
- Net Profit Margin is 13.24 %
- EPS at ₹ 1.61

**Commenting on the performance, Mr. Atul Vasani, Chairman and Managing Director of Vaishali Pharma Limited said,** "We are pleased to present the results for H1 of FY24. Our unwavering dedication to innovation, commitment to maintaining high-quality standards, and the strategic expansion of our global footprint through valuable partnerships have been instrumental in driving our success.

Our venture into the Nutraceutical Products segment, in addition to our ongoing collaborations and alliances, is poised to serve as pivotal growth catalysts in the future. We eagerly anticipate the continuation of our journey towards excellence, with the utmost focus on delivering value to our stakeholders and making significant contributions to the enhancement of healthcare worldwide."

### **About Vaishali Pharma Limited:**

**Vaishali Pharma Limited (NSE – VAISHALI)**, established in 1989 in Mumbai, specializes in the production and marketing of a diverse range of pharmaceutical products, including APIs, formulations, surgical products, veterinary supplements, herbal items,

nutraceuticals, and oncology products. Their portfolio serves both human and animal healthcare needs.

With a domestic presence in Maharashtra, they've expanded globally through partnerships in the Democratic Republic of Congo, Kenya, and Russia. Notably, they've formed a strategic partnership with Sankalp Life Care, a leading nutraceuticals manufacturer, to manage Sankalp LifeCare's domestic and international marketing operations.

In FY23, the company reported Revenue of ₹ 69.66 Crore, EBITDA of ₹ 11.36 Crore and PAT of ₹ 6.60 Crore.

**Disclaimer:**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

**For Further Information Please Contact:**

Sunil Mudgal  
Kirin Advisors Private Limited  
[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)  
M - 9869275849